Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.

Por Cherrington, J M, Mulato, A S, Fuller, M D, Chen, M S
Publicado em 1996

Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy

Por Mulato, A. S., Lamy, P. D., Miller, M. D., Li, W.-X., Anton, K. E., Hellmann, N. S., Cherrington, J. M.
Publicado em 1998

K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.

Por Gu, Z, Salomon, H, Cherrington, J M, Mulato, A S, Chen, M S, Yarchoan, R, Foli, A, Sogocio, K M, Wainberg, M A
Publicado em 1995

Comparative kinetic analyses of interaction of inhibitors with Rauscher murine leukemia virus and human immunodeficiency virus reverse transcriptases.

Por Cherrington, J M, Fuller, M D, Mulato, A S, Allen, S J, Kunder, S C, Ussery, M A, Lesnikowski, Z, Schinazi, R F, Sommadossi, J P, Chen, M S
Publicado em 1996

9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.

Por Van Rompay, K K, Cherrington, J M, Marthas, M L, Berardi, C J, Mulato, A S, Spinner, A, Tarara, R P, Canfield, D R, Telm, S, Bischofberger, N, Pedersen, N C
Publicado em 1996